Download video

John P. Leonard, MD, on the FDA Approval of Tazemetostat for Follicular Lymphoma

195 views

Cancer Network

4 years ago

John P. Leonard, MD, on the FDA Approval of Tazemetostat for Follicular Lymphoma

John P. Leonard, MD, on the FDA Approval of Tazemetostat for Follicular Lymphoma

John P. Leonard, MD, on the FDA Approval of Tazemetostat for Follicular Lymphoma
8:58
John P. Leonard, MD, on the FDA Approval of Tazemetostat for Follicular Lymphoma
by Cancer Network
Accelerated Approval of Tazemetostat For Follicular Lymphoma
3:55
Accelerated Approval of Tazemetostat For Follicular Lymphoma
by CheckRare
Dr. Leonard on the FDA Approval of Tazemetostat in Follicular Lymphoma
1:16
Dr. Leonard on the FDA Approval of Tazemetostat in Follicular Lymphoma
by OncLive
Tribute to John P. Leonard, MD at the 2018 Annual Gala
6:04
Tribute to John P. Leonard, MD at the 2018 Annual Gala
by Lymphoma Research Foundation
Dr. John Leonard on When to Treat Patients With Follicular Lymphoma
1:07
Dr. John Leonard on When to Treat Patients With Follicular Lymphoma
by Targeted Oncology
John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas
1:01
John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas
by OBRoncology
John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms
1:40
John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms
by OBRoncology
Dr John P Leonard Live Q\&A Living with Follicular Lymphoma
1:06:04
Dr John P Leonard Live Q\&A Living with Follicular Lymphoma
by Nicky Greenhalgh
Dr. John Leonard at ASCO 2018: Vitamin D Supplementation
0:51
Dr. John Leonard at ASCO 2018: Vitamin D Supplementation
by Lymphoma Cancer Treatment NY - Weill Cornell
Expert Perspectives: Lymphoma
16:16
Expert Perspectives: Lymphoma
by HMP Education
Tazemetostat in combination with lenalidomide and rituximab for R\/R follicular lymphoma
1:48
Tazemetostat in combination with lenalidomide and rituximab for R\/R follicular lymphoma
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dr. Skarbnik on the Approval of Tazemetostat in Relapsed\/Refractory Follicular Lymphoma
0:57
Dr. Skarbnik on the Approval of Tazemetostat in Relapsed\/Refractory Follicular Lymphoma
by OncLive
John P. Leonard, MD, on the role social media plays in medicine
1:46
John P. Leonard, MD, on the role social media plays in medicine
by OBRoncology
Dr. Maddocks on the Role of Tazemetostat in EZH2-Mutant Follicular Lymphoma
1:11
Dr. Maddocks on the Role of Tazemetostat in EZH2-Mutant Follicular Lymphoma
by OncLive
Leslie Popplewell, MD, provides thoughts on the unique MOA on the newly FDA approved tazemetostat
3:24
Leslie Popplewell, MD, provides thoughts on the unique MOA on the newly FDA approved tazemetostat
by OBRoncology
Dr. Burke on Tazemetostat’s Mechanism of Action in EZH2-Mutated Follicular Lymphoma
1:35
Dr. Burke on Tazemetostat’s Mechanism of Action in EZH2-Mutated Follicular Lymphoma
by OncLive
FDA Approval in CLL and FL, Partial Hold Lifted in Tazmetostat Trials, and More
11:13
FDA Approval in CLL and FL, Partial Hold Lifted in Tazmetostat Trials, and More
by OncLive
Dr. Leslie on Phase 1b Trial of Tazemetostat Plus Lenalidomide\/Rituximab in Follicular Lymphoma
1:15
Dr. Leslie on Phase 1b Trial of Tazemetostat Plus Lenalidomide\/Rituximab in Follicular Lymphoma
by OncLive
Dr. Skarbnik on Future Combination Therapies With Tazemetostat in Follicular Lymphoma
1:08
Dr. Skarbnik on Future Combination Therapies With Tazemetostat in Follicular Lymphoma
by OncLive
The recent FDA approval of ponatinib for Ph+ ALL following success in the PhALLCON trial
0:44
The recent FDA approval of ponatinib for Ph+ ALL following success in the PhALLCON trial
by VJHemOnc – Video Journal of Hematology \& HemOnc